https://pledge-tx.com/publications/il-18bp-inhibition-elicits-adaptive-checkpoint-expression-and-enables-novel-immune-checkpoint-inhibitor-ici-combinations-in-colon-cancer/ 2025-11-11T14:01:56+00:00 https://pledge-tx.com/wp-content/uploads/2025/11/IL-18BP-Inhibition-Elicits-Adaptive-Checkpoint-Expression-and-Enables-Novel-Immune-checkpoint_inhibitor-ICI-Combinations-in-Colon-Cancer.jpg https://pledge-tx.com/publications/bk-polyomavirus-vp1-genotyping-predicts-antibody-escape-and-provides-guardrails-for-vp-1-targeting-therapy-american-society-of-nephrology-ans-kidney-week-november-6-9-2025/ 2025-11-13T13:03:49+00:00 https://pledge-tx.com/wp-content/uploads/2025/11/ASN-2025_Orthogon-Therapeutics-Virology_Pledge-Therapeutics.jpg https://pledge-tx.com/publications/pledge-ai-content/ 2025-11-13T13:04:06+00:00 https://pledge-tx.com/wp-content/uploads/2025/11/Picogen_-A-Generative-AI-Model-That-Unlocks-Shallow-PPI-Interfaces-Across-Oncology-Targets-and-Designs-Novel-Ligands-Including-TEAD-YAP-Inhibitors_.jpg https://pledge-tx.com/publications/a-structure-enabled-hhla2-targeted-bispecific-t-cell-engager-cfx11-demonstrates-potent-antigen-dependent-anti-tumor-activity-in-preclinical-solid-tumor-models/ 2026-03-27T17:08:04+00:00 https://pledge-tx.com/wp-content/uploads/2026/03/ImmuneOncology-Pledge-Therapeutics-ConformationX-Therapeutics-scaled.png